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Background: Increased nocturnal airways narrowing (NAN) in asthma is thought o occur as 
the result of intensification of inflammatory processes in the airways. In this study we 
investigated the presence of inflammatory cells and mediators in bronchoalveolar lavage 
(BAL) fluid and peripheral blood (PB) and assessed their relationship with the occurrence of 
increased NAN. 
Methods: BAL fluid and PB samples were assessed at 16:00 and 04.'00 hours, separated by 7 
days or more, in eight nonatopic healthy subjects (group 1) and 17 atopic subjects with 
asthma who were using inhaled bronchodilators only. The latter subjects were prospectively 
assigned to groups with and without NAN, as defined by a mean circadian peak expiratory 
flow variation of less than 15% (group 2) and 15% or more (group 3), respectively. 
Results: Significantly higher eosinophil numbers and inflammatory activation products 
(eosinophil cationic protein, eosinophil-derived neurotoxin, histamine) were found in BAL 
fluid and PB from subjects with asthma in comparison with control subjects. However, 
increased NAN was not generally associated with a circadian fluctuation in cell number and 
inflammatory mediators in BAL fluid and PB. No differences in inflammatory cell numbers 
existed that distinguished between groups 2 and 3. However, in group 3 significantly higher 
BAL prostaglandin D2 levels (70 vs 24 pg/ml; range, 28 to 102 vs 11 to 90 pg/ml; p = 0.04) 
and serum eosinophil cationic protein levels (17.6 vs 16.1 ng/ml; range, 6.3 to 17.5 vs 6.3 to 
60.3 ng/ml; p --- 0.03) at 16.'00 hours were detected compared with group 2. 
Conclusions: Our findings suggest hat increased NAN is more likely to occur in subjects with 
asthma with ongoing increased cellular activation during the day. (J ALLERGY CLIN 1MMUNOL 
1995,'96:219-29.) 
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Increased nocturnal airways narrowing (NAN) 
in asthma is thought to occur as the result of 
intensification of inflammatory processes in the 
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airways of subjects with nocturnal asthma, as has 
been suggested by an increase in (indirect) airways 
hyperresponsiveness at night 1 and findings that 
adequate antiinflammatory treatment with inhaled 
corticosteroids reduce the circadian variation in 
airways obstruction and responsiveness? 
Inflammatory conditions may be associated with 
an increased influx of cells into the airway wall, 
together with marked shifts in cell populations in 
the bronchoalveolar lavage (BAL) fluid. So far, 
however, conflicting results have been reported as 
to nocturnal increases in cell numbers and mor- 
phology, as analyzed in BAL fluid from subjects 
with nocturnal asthma?, 4 In addition, peripheral 
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Abbreviations used 
NAN: 
BAL: 
BSA: 
ECP: 
EDN: 
FEVa: 
PB: 
PBS: 
PC2o: 
PEF: 
PG: 
RIA: 
TxB2: 
Nocturnal airways narrowing 
Bronchoalveolar lavage 
Bovine serum albumin 
Eosinophil cationic protein 
Eosinophil-derived neurotoxin 
Forced expiratory volume in 1 second 
Peripheral blood 
Phosphate-buffered saline solution 
Provocative concentration of a stimulus 
that causes a 20% decrease in FEV~ 
Peak expiratory flow 
Prostaglandin 
Radioimmunoassay 
Thromboxane B 2 
blood (PB) eosinophil numbers and their activa- 
tion parameters during the night in subjects with 
nocturnal asthma have been found to be either 
increased 5, 6 or decreased, y and conflicting results 
have been reported as to PB histamine levels as 
well. y, g From the various studies it can often not be 
deduced whether the circadian variations are due 
to pathologic processes underlying nocturnal 
asthma or whether they belong to normal physio- 
logic circadian rhythms. For instance, both in 
normal and asthmatic subjects circadian rhythms 
exist in PB leukocyte number and their functional 
activity. 9 Similar chronobiologic rhythms in cell 
number and activity in the airways can be postu- 
lated. So far, however, circadian variations in 
inflammatory cells in BAL fluid of healthy persons 
have scarcely been investigated. 
The aim of this study was to investigate the 
presence of inflammatory cells and mediators in 
BAL fluid and PB at 16:00 and 04:00 hours from 
healthy subjects and from atopic patients with 
asthma and to determine their relationship with 
the occurrence of increased NAN in asthma, as 
assessed by measurement of the circadian peak 
expiratory flow (PEF) rhythm. Eosinophils and 
mast cells are considered as principal effector 
cells?0, n Their activation parameters, as assessed 
by EG2+-staining cells, eosinophil cationic protein 
(ECP), eosinophil-derived neurotoxin (EDN), his- 
tamine, and prostanoids, have been found to be 
increased in the BAL fluid of patients with stable 
and symptomatic asthma? 246 These cell types and 
activation parameters were assessed in BAL fluid, 
whereas in PB eosinophil numbers and ECP levels 
were determined. 
METHODS 
Subjects 
Eight healthy subjects and 17 subjects with asthma 
(age range, 18 to 45 years) participated in the study 
(Table I). The subjects were recruited through adver- 
tisements in local newspapers and from the outpatient 
clinic of our hospital. The study was approved by the 
ethical committee of the hospital, and written informed 
consent was given by each subject. 
At entry to the study the selected healthy volunteers 
had no history of lung disease or allergy; no atopy, as 
demonstrated bynegative results of intracutaneous tests 
against 18 common aeroallergens, expressed as hista- 
mine equivalent wheal size less than 0.7 (Diephuis 
Laboratories, Groningen, The Netherlands); no airway 
response on provocation with methacholine, as deter- 
mined by a fall in forced expiratory volume in 1 second 
(FEV1) of less than 10% after inhalation of methacho- 
line bromide in a concentration of 9.8 mg/ml (2-minute 
inhalation, 5-minute interval); and no upper espiratory 
infections within 1 month before the study and no 
concomitant diseases. 
Subjects with asthma were prospectively selected on 
the basis of a history of episodic dyspnea or wheezing 
consistent with the clinical diagnosis of asthma17; atopy, 
as determined by positive results of intracutaneous tests 
against house dust mite or two of 18 other tested 
common aeroallergens (histamine quivalent wheal size 
->0.7); FEV1 greater than 1.50 L and 70% or more of 
predicted value; postbronchodilator FEV1 (400 Ixg sal- 
butamol with a spacehaler) 80% or more of predicted 
value; airway hyperresponsiveness to methacholine, de- 
fined as the provocative concentration of methacholine 
bromide that caused a 20% fall in FEV1 (PC2o) of 9.8 
mg/ml or less (2-minute inhalation, 5-minute interval); 
no use of oral corticosteroids within 2 months before 
the study; no upper respiratory infections within 1 
month before the study and no other concomitant 
diseases. 
Study design 
In the subjects with asthma inhaled corticosteroids 
and cromolyns were stopped 4weeks before the start of 
the study. Until the last bronchoscopy subjects were 
allowed to use inhaled bronchodilators only ([32-agonists 
or ipratropium bromide). 
The week before the study PEF values were recorded 
for 3 days at 08:00, 12:00, 16:00, 20:00, 24:00, and 4:00 
hours. Bronchodilators were withheld. The best of three 
PEF maneuvers was recorded. The mean circadian PEF 
variation of the 3 days was defined as (Highest 24 Hour 
Value - Lowest 24-Hour Value) + Mean 24-Hour 
Value. Subjects were prospectively selected in three 
groups: group 1 consisted of healthy volunteers, whereas 
subjects with asthma were assigned to group 2 if the 
mean circadian PEF variation was less than 15% and to 
group 3 if the PEF variation was 15% or greater. 
Nocturnal asthma symptoms were scored on the basis of 
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TABLE I. Subject characteristics 
No. of 
positive PC20 
Age (yr)/ Smoking skin test FEV1 methacholine 
gender history Medication* results (% predicted) (mg/ml) 
NAN PEF rhythm 
scorer (%)$ 
Group 1 (Subject No.) 
1 44/M - - 0 121 >9.8 
2 21/F - - 0 107 >9.8 
3 20/M - - 0 88 >9.8 
4 32/M - - 0 92 >9.8 
5 27/F - - 0 99 >9.8 
6 21/M - - 0 116 >9.8 
7 34/F - - 0 125 >9.8 
8 22/F - - 0 93 >9.8 
Group 2 (Subject No.) 
1 30/M - B 7 100 1.33 
2 20/M - B 6 105 1.88 
3 19/M - CR 6 80 1.64 
4 22/F - B 7 90 0.34 
5 18/M - B, CS 6 82 0.63 
6 29/F - B, CS 6 97 1.68 
7 40/M - B 7 94 0.36 
Group 3 (Subject No.) 
1 41/M - A 2 114 0.73 
2 22/M - B, CS 8 90 0.66 
3 22/F - B, CS 7 69 0.04 
4 32/F - A, CS 3 94 0.60 
5 29/M - B 4 80 0.64 
6 21/F - B 2 98 0.96 
7 21/F + B 8 68 0.08 
8 26/F + B, CS 8 82 0.17 
9 41/F - B, CS 7 92 0.37 
10 20/F - B, CR 5 88 0.04 
4 
6 
8 
8 
9 
9 
11 
11 
6 
8 
10 
11 
12 
13 
14 
19 
20 
23 
24 
25 
28 
29 
31 
44 
46 
A, Anticholinergic drugs; B, [32-adrenergic drugs; CR, cromoglycate; CS, corticosteroid. 
*Regular inhaled therapy until 4 weeks before participation i the study. 
tAwakening because of nocturnal dyspnea: 0 = never, 1 = sometimes, 2 = every night in previous 2 weeks. 
SExpressed as (Highest 24-Hour Value - Lowest 24-Hour Value) + Mean 24-Hour Value. 
nocturnal awakening caused by nocturnal dyspnea in the 
last week, as follows: 0 = never, 1 = sometimes, 2 = 
every night. FEV 1 and airway hyperresponsiveness to 
methachol ine were assessed within 5 days before the first 
bronchoscopy. 
Thirty minutes before each bronchoscopy, FEV 1 mea-  
surements  were performed and PB samples were taken. 
Subjects rested for 15 minutes before the daytime lung 
function measurements.  At night subjects were admitted 
to the hospital at 22:00 hours and were awakened 15 
minutes before the measurements.  Bronchodi lator ther- 
apy was withheld 8 hours before the pulmonary function 
tests. Bronchoscopy was performed at 16:00 hours (4:00 
PM) and 04:00 hours (4:00 AM) on two different days, 
separated by at least 7 days. Nineteen subjects under-  
went their first bronchoscopy at 16:00 hours, and five at 
04:00 hours. 
Pulmonary function and inhalation 
provocation tests 
PEF  values were recorded with a Wright mini peak 
flow meter. FEVa was measured with a cal ibrated water- 
sealed spirometer according to standardized guide- 
lines, 18 with the best of three measurements being used 
for analysis. Airway responsiveness to methachol ine was 
measured by a 2-minute tidal breathing method. 19 Pro- 
vocative concentrat ion of a stimulus that causes a 20% 
decrease in FEV 1 (PC2o) were calculated by l inear 
interpolation of the last two points of the log concentra- 
t ion response curve. 
Bronchoscopy procedure 
Fiber-optic bronchoscopy was undertaken according 
to guidelines described by the Amer ican Thoracic Soci- 
ety. 2° Premedicat ion consisted of intramuscular injec- 
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tion of 0.5 mg atropine and inhalation of 200 p~g 
salbutamol via a Volumatic spacer device (Glaxo, 
Utrecht, The Netherlands). Lidocaine 4% was applied as 
local anesthetic into the upper airways and bronchial 
tree. Supplementary oxygen was available. Bronchos- 
copy was performed with an Olympus B1 IT10 flexible 
fiber-optic bronchoscope (Olympus Optical Co., Tokyo, 
Japan). The instrument was inserted through the mouth 
and wedged in the lateral segment of the right middle 
lobe. Subsequently, 10 aliquots of 20 ml sterile phos- 
phate-buffered saline solution (PBS) of 37 ° C were in- 
stilled and recovered by gentle suction ( -40  cm H20 ) 
after each aliquot. The BAL fluid was collected in poly- 
propylene tubes, which were immediately placed in ice. 
Laboratory techniques 
The BAL fluid was pooled in two fractions: pool 1 
consisted of the fluid recovered from the first two 20 ml 
quantities of PBS instilled, which contained constituents 
from the proximal airways; pool 2 comprised the fluid 
from the remaining 8 quantities of 20 ml. Cell numbers 
and activation parameters were assessed in the first 
fraction. Because of a limited amount of BAL fluid in 
this fraction, the eicosanoids had to be determined in 
pool 2. The lavage fluid was filtered through a 100 ixm 
pore filter of a venous infusion system (Curapharm, 
Medica B.V., Hospital Supplies, Hertogenbosch, The 
Netherlands) to remove mucus and centrifuged at 400 g 
at 4 ° C for 5 minutes. The BAL supernatant was stored 
at -80°C until further determination. The cell pellets 
were resuspended in 1 ml PBS with 0.5% heat-inacti- 
vated bovine serum albumin (BSA) (PBS/BSA 0.5%). 
Total leukocyte counts in PB and BAL cell suspen- 
sions were measured in a Coulter Counter (model S-plus 
VI; Coulter Electronics, Hialeah, Fla.), and viability was 
assessed by cellular exclusion of trypan blue. Cytocen- 
trifuged preparations of both pools of BAL fluid were 
made from 100 Ixl fractions of the BAL cell suspension, 
diluted to a volume of 0.25 × 106 cells/ml in PBS/BSA, 
0.5%, with a Shandon Cytospin-2 centrifuge (Shandon 
Inc., Pittsburgh, Pa.). After preparations were stained 
with May-Grtinwald-Giemsa, the average of 300 cell 
counts on two slides was taken as the differential cell 
count. Additional cytocentrifuged preparations were 
sealed in plastic and stored at -80  ° C for future staining 
and analysis. PB eosinophil numbers were counted in a 
Bfirker chamber after staining with eosin. 
Activated eosinophils in the BAL fluid were identified 
by immunostaining of acetone-fixed cytocentrifuge prep- 
arations with the monoclonal antibody EG2 (Sanbio, 
Uden, The Netherlands), which detects a cleaved part of 
the ECP. A two-step alkaline phosphatase procedure 
was performed, according to the method described by 
Tai et al., 21 with minor modifications. The slides were 
incubated with 50 ixl EG2 solution (1:50) for 60 minutes. 
As a control for false-positive counting, the primary 
antibody was omitted or an irrelevant antibody was used 
as a first step. The slides were then incubated for 30 
minutes with an alkaline phosphatase-conjugated rabbit 
anti-mouse IgG antibody (1:40) (Sigma, St. Louis, Mo.) 
supplemented with 5% human AB serum, followed by 
an alkaline phosphatase-conjugated goat anti-rabbit 
IgG antibody (1:40) supplemented with 5% human AB 
serum. The phosphatase r activity was demonstrated by
Fast Red (Sigma) (1 mg/ml) in tris(hydroxymethyl) 
aminomethene-HC1 buffer, 0.1 mol/L pH 8.2; containing 
0.2 mg/ml naphthol AS-MX (Sigma) with 2 mmol/L 
levamisole (Sigma) to inhibit endogenous alkaline phos- 
phatase. The slides were counterstained with fresh May- 
ers' hematoxylin. EG2 + cell counts were performed on 
two slides and the average counts of 500 cells on each 
slide was taken as the definitive number of positive cells. 
Only intact and unclustered cells were counted. Total 
EG2 + cell counts were calculated from the total leuko- 
cyte number per milliliter of BAL fluid. 
ECP and EDN determination i serum and BAL fluid. 
Serum was obtained after coagulation of the blood for 1 
hour at room temperature. The supernatant was centri- 
fuged twice for 10 minutes at 2000 g and stored at 
-80°C until analysis. ECP was measured in serum, 
whereas ECP and EDN were determined in unprocessed 
BAL supernatants from pool 1. This was performed by 
double-antibody radioimmunoassays (RIA) (Pharmacia 
Diagnostics AB, Uppsala, Sweden), as described previ- 
ously. 22,23 The detection level in both assays was 0.1 
ng/ml. 
Histamine determination i BilL fluid. Histamine was 
determined in unprocessed lavage supernatants from 
pool 1, with the RIA procedure from Immunotech 
(Westbrook, Maine), in accordance with the manufac- 
turer's protocol. 
Eicosanoid etermination. Immediately after the BAL 
procedure 20 ml of BAL supernatant from pool 2 was 
processed on C18 SepPak cartridges (Millipore, Bed- 
ford, Mass.) as described previously, 24eluted with 2.5 ml 
methanol and stored at -80  ° C until analysis. Samples of 
200 ~xl eluted fluid were pipetted into polypropylene 
tubes and dried with a Savant sample concentrator. 
After dissolving in 300 txl assay buffer, thromboxane B 2 
(TxB2) level was determined by means of a [3HI RIA 
with antisera from Advanced Magnetics Inc. (Cam- 
bridge, Mass.) and tritium-labeled compounds from 
Amersham International p c. (Amersham, Buckingham- 
shire, U.K.; prostaglandin (PG) D 2 and PGF2~ were 
tritium-labeled kits obtained from Amersham UK. 24 
6-Keto PGFI~ (6kPGFa~) was determined by means of a 
iodine 125-labeled RIA kit (Du Pont de Nemours, 
Dreieich, Germany). Leukotriene C4/D4/E 4 was mea- 
sured at room temperature in a microtiter enzyme 
immunoassay according to protocol (Biotrak, Amer- 
sham, UK). Crossreactivities for each assay to related 
compounds were negligible or less than 2% at B/Bo 50%. 
Data analysis 
PC2o values were analyzed after base 2 logarithmic 
transformation and expressed as the geometric mean 
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PC2o value. After verification of the normal distribution, 
changes in values of lung function parameters within 
subjects were analyzed with the Student paired two- 
tailed t test and between groups with the Student t test 
for unpaired observations. Nonparametric tests were 
used to analyze the cell number and activation parame- 
ters, the number of positive skin test results, and noc- 
turnal asthma score. The Mann-Whitney U test was used 
to compare data between groups, and Wilcoxon's 
matched[ signed-rank test was applied for within-group 
analyses. Correlations between the circadian PEF vari- 
ations, and lung function or cell parameters, were made 
by Spearman's rank correlation tests. All analyses were 
performed with the SPSS/PC ÷ V 4.01 software package 
(SPSS Inc., Chicago, ILL). Values ofp 0.05 or less were 
considered statistically significant. 
RESULTS 
Subjects 
Subject characteristics are listed in Table I. 
Group 1 consisted of healthy volunteers. Seven 
subjects with asthma were assigned to group 2 
(mean circadian PEF variation, <15%) and 10 to 
group 3 (mean circadian PEF variation, >-15%). 
Mean circadian PEF rhythms in the control group 
and group 2 were not significantly different from 
each other. Age and gender were not significantly 
different among the three groups, nor were the 
number of positive skin test results and mean 
percentage of predicted FEV, between the two 
asthma groups. Mean percentage of predicted 
FEV 1 was significantly lower in both asthma 
groups as compared with the healthy control group 
(p < 0.05). 
Subjects with asthma in group 3 scored signifi- 
cantly higher on awakening because of nocturnal 
dyspnea. (p = 0.03), and their geometric mean PC20 
from methacholine was significantly lower as com- 
pared with the subjects with asthma in group 2 (0.26 
and 0.9:1 mg/ml, respectively; p = 0.02). The circa- 
dian PEF variation of all subjects with asthma 
was significantly correlated with the PC20 metha- 
choline values (r = -0.65, p = 0.007) and with 
the nocturnal asthma symptom score (r = 0.73, 
p = 0.009). 
FEV., measurements 
Mean FEV~ in group 3 decreased significantly at 
night as compared with the 16:00 hour value (from 
87.5% + 13.7% to 75.7% + 19.2%, p = 0.005), 
whereas this was less pronounced in group 2 (from 
92.6% :_~ 9.2% to 88.1% + 10.1%,p = 0.09). In the 
healthy control group no differences were found- 
between the 16:00 and 04:00 hour values (105% _+ 
14.2% and 105% _+ 13.2%, respectively). 
Bronchoscopy procedure 
Results of BAL parameters in group 3 are based 
on data from nine subjects (subject 4 in this group 
refused a second bronchoscopy). 
BAL cell analysis 
The volume of fluid recovered, and total and 
differential cell numbers, in pool 1 are shown in 
Table II. The volume of fluid recovered was lower 
in the asthmatic groups than in the normal volun- 
teers, but this reached significance only at 04:00 
hours (p = 0.04). Mean total and differential cell 
numbers per milliliter of BAL fluid were not 
significantly different among the various groups at 
the different ime points. 
Eosinophil numbers were higher in the subjects 
with asthma as compared with the control group 
(16:00 hours, p -- 0.004; 04:00 hours, p = 0.05) but 
were not significantly different between the two 
asthmatic groups. In groups 1 and 2 the numbers 
tended to increase at night and ran parallel with 
increased numbers of neutrophils at 04:00 hours 
(p = 0.02 and p = 0.03, respectively). 
EG2 + cell numbers showed the same pattern 
as the eosinophil numbers (Table II). The num- 
bers were significantly higher in the subjects with 
asthma than in the control subjects at 16:00 
hours (p < 0.001), with the same trend at 04:00 
hours. No statistical difference was found be- 
tween both asthmatic groups. The numbers of 
EG2 + cells were always higher at 04:00 hours 
than at 16:00 hours and reached significance in 
group 2 (p = 0.04). 
BAL inflammatory mediator levels 
In all subjects with asthma EDN and histamine 
values were higher than in the control group and 
reached significance at 16:00 hours (p = 0.04 and 
p = 0.003, respectively) (Fig. 1). There was no 
statistically significant difference in EDN and his- 
tamine levels between the asthma groups at both 
time points. No significant variation in EDN and 
histamine levels between 04:00 and 16:00 hours 
was found in the three groups. In contrast to EDN, 
most ECP levels were less than the detection level 
of 0.1 ng/ml and were therefore not suitable to 
detect differences between the time points among 
the various groups. 
Eicosanoid levels in BAL fluid are shown in Fig. 
2. Because of the limited recovery of BAL fluid, 
eicosanoid levels could not be assessed in two 
subjects with asthma, one from group 2 and one 
from group 3. Significantly higher levels of PGD 2 
were found in group 3 as compared with the other 
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TABLE II. Ce l lu la r  aspects  o f  BAL  f lu id  (poo l  1) 
Group 2 (asthma with PEF Group 3 (asthma with PEF 
Group 1 (control) rhythm <15%) rhythm >15%) 
Variable 16:00 04:00 16:00 04:00 16:00 04:00 
Recovery (%) 48.8 (37.5-57.5) 47.5 (40.0-57.5) 45.0 (25.0-57.5) 36.3 
Total leukocytes 50.4 (8.6-199) 64.3 (28.0-87.9) 48.9 (26.5-86.7) 68.5 
(103 cells/ml) 
Alveolar macro- 48.8 (7.7-193) 56.7 (24.6-72.8) 46.1 (24.6-79.5) 64.4 
phages (103 
cells/ml) 
Mast cells 0.0 (0.0-0.04) 0.0 (0.0-0.1) 0.0 (0.0-0.05) 0.0 
(103 cells/ml) 
Lymphocytes 1.5 (0.1-2.6) 1.5 (0.0-3.5) 1.4 (0.6-2.0) 2.2 
(103 cells/ml) 
Neutrophils 0.7 (0.3-3.6) 2.9 (1.4-14.9)? 0.1 (0.0-1.2) 2.5 
(103 cells/ml) 
Eosinophils 0.2 (0.0-0.8) 0.6 (0.0-5.0) 1.1 (0.5-4.6):~ 2.6 
(103 cells/ml) 
EG2 + cells 0.1 (0.0-0.2) 0.2 (0.0-2.6) 0.6 (0.1-6.7)§ 2.3 
(103 cells/ml) 
Epithelial cells 0.1 (0.0-1.0) 0.1 (0.0-3.3) 0.0 (0.0-2.1) 0.1 
(103 cells/ml) 
(22.5-50.0)* 40.0 (25.0-55.0) 32.5 (17.5-50.0)* 
(30.7-164) 51.8 (25.5-155) 71.0 (17.8-249) 
(18.4-146) 50.4 (19.5-151) 68.0 (15.2-171) 
(0.0-0.0) 0.0 (0.0-0.2) 0.0 (0.0-0.0) 
(0.7-6.0) 0.8 (0.0-2.7) 1.0 (0.1-2.9) 
(0.0-6.5)t 0.5 (0.0-19.5) 0.2 (0.0-7.1) 
(1.2-6.7)$, 0.7 (0.2-4.0)$ 1.5 (0.1-75.1) 
(0.7-14.7)§ 0.6 (0.1-2.0)§ 1.0 (0.0-16.7) 
(0.0-0.2) 0.1 (0.0-2.5) 0.2 (0.0-2.8) 
Values expressed asmedians, with ranges in parentheses. 
*All subjects with asthma, p = 0.04 compared with 16:00 hour value; p = 0.01 compared with 4:00 hour value in group 1. 
?p < 0.05 compared with 16:00 hour value within group. 
:~All subjects with asthma: 16:00 hours, p -< 0.004; and 04:00 hours, p = 0.05, compared with value of control group. 
§All subjects with asthma: 16:00 hours, p < 0.001; and 04:00 hours, p = 0.001, compared with value of control group. 
groups at both time points (p -< 0.04). Further- 
more, TxB a levels in group 3 were significantly 
higher as compared with group 2 at both time 
points (p = 0.04), but this did not reach signifi- 
cance as compared with the control group. In- 
creased levels of leukotriene C4 were found in 
group 3 at 04:00 hours as compared with the other 
groups, reaching significance with the control group 
(p = 0.03). No significant differences in PGF2~ and 
6kPGFa~ levels were observed among the various 
groups. No significant variations in eicosanoid levels 
between 04:00 and 16:00 hours within the three 
groups were found. 
Peripheral blood analysis 
Total leukocyte counts (Table III) did not show 
a statistically significant difference between ormal 
subjects, all subjects with asthma, or the asthma 
subgroups at 16:00 and 04:00 hours. Furthermore, 
there were no variations between 04:00 and 16:00 
hours in the three groups. 
Eosinophil numbers in PB were significantly 
higher in all subjects with asthma s compared with 
the control subjects at 16:00 hours and 04:00 hours 
(p - 0.01), but there was no significant difference 
between the two asthma groups. Mean total co- 
sinophil counts were increased in all groups at 
04:00 hours compared with the 16:00 hour val- 
ues. This reached significance in group 2 (p = 
0.05). 
Mean serum ECP level at 16:00 hours were not 
significantly different between groups 1 and 2, 
whereas this level was significantly higher in group 
3 (p -< 0.03). At 04:00 hours levels in both asthma 
groups were significantly higher than in the con- 
trol group (p - 0.01), whereas no significant 
difference was found between the two asthma 
groups. Mean serum ECP was significantly in- 
creased at night in group 2 (p = 0.02) but not in the 
other groups. 
Correlations wi th  circadian PEF variation in 
subjects w i th  asthma 
Bronchoalveolar lavage. Eosinophil and EG2 + 
cell numbers, mast cells, histamine levels, and 
other eicosanoid levels in the BAL fluid at 16:00 
and 04:00 hours and changes between 04:00 and 
16:00 hours were not significantly correlated with 
the circadian PEF variation in subjects with 
asthma, although a trend was found for higher 
PGD 2 levels at 16:00 hours and for higher EDN 
levels at 04:00 hours with a bigger circadian PEF 
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FIG. 1. EDN (upper panel) and histamine (Iower panel) levels in BAL fluid (pool 1) at 16:00 and 
04:00 hours in control subjects (group 1), and in subjects with asthma with circadian PEF 
variation less than 15% (group 2) and 15% or greater (group 3). Individual values are represented 
by dots; median values by horizontal bars. For details, see Results. 
rhythm (r = 0.49 and  r = 0.47, respect ive ly ;  p = 
0.06). 
Peripheral blood. ECP values at 16:00 hours 
(also without outlier of 60.3) correlated signifi- 
cantly with the circadian PEF variation in subjects 
with asthma (r = 0.61, p = 0.01) (Fig. 3). Total 
eosinophil numbers at 16:00 and 04:00 hours, and 
variations between 04:00 and 16:00 hours, were not 
significantly correlated with the circadian PEF 
variation. 
DISCUSSION 
We investigated the presence of inflammatory 
cell numbers and their activation products in BAL 
fluid and PB and determined their relationship 
with the occurrence of increased NAN in asthma, 
as assessed by measurement of the circadian PEF 
variation. Overall, higher eosinophil numbers and 
levels of inflammatory cell activation products 
were found in BAL fluid and PB from subjects with 
asthma in comparison with control subjects. How- 
ever, in subjects with asthma with increased circa- 
dian PEF rhythm, no specific circadian change in 
inflammatory cells and the investigated mediators 
occurred. Most activation parameters at 16:00 and 
04:00 hours did not differentiate this group from 
subjects with asthma without increased NAN. In- 
terestingly, a number of eicosanoid levels in BAL 
fluid (PGD 2 and TxB2) and serum ECP levels were 
significantly higher in daytime in subjects with 
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FIG. 2. Eicosanoid levels in BAL fluid (pool 2) at 16:00 and 04:00 hours in control subjects (group 
1) and in subjects with asthma with circadian PEF variation less than 15% (group 2) and 15% or 
greater (group 3). Individual values are represented by large dots; median values expressed by 
horizontal bars, For details, see Results. 
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TABLE III. Cellular aspects of PB 
Group 2 (asthma with PEF Group 3 (asthma with PEF 
Group 1 (control) rhythm <15%) rhythm >15%) 
16:00 04:00 16:00 04:00 16:00 04:00 
Total leukocytes 
(109 cells/L) 
Eosinophils 
(106 cells/L) 
ECP (n~]ml) 
7.8 (5.2-8.7) 8.1 (4.9-9.3) 7.1 (4.5-9.2) 7.3 (5.0-9.7) 7.2 (4.9-10.4) 7.6 (5.6-9.0) 
88 (22-297) 198 (22-352) 264 (99-473) 308 (231-1002)* 276 (44-605)1" 308 (121-1496)t 
13.6 (5.5-16.1) 10.9 (6.5-16.8) 16.1 (6.3-17.5) 16.9 (11.2-28.6)* 17.6 (16.4-60.3)* 17.8 (15.9-45.1)I" 
Values expressed as medians, with ranges in parentheses. 
*p -< 0.02 compared with 16:00 value within group. 
?All subjects with asthma t 16:00 and 04:00 hours, p -< 0.02, compared with value of control group. 
Sp <- 0.03 compared with 16:00 values for groups 1 and 2. 
asthma, with increased circadian PEF variation as 
compared with those without increased circadian 
PEF variation. A significant cx~rrelation was found 
between serum ECP and circadian PEF variation in 
subjects with asthma. In addition, a trend was ob- 
served toward a correlation between 16:00 hours 
BAL PGD 2 levels and circadian PEF variation in 
subjects with asthma, but no correlation between the 
TxB 2 levels and the circadian PEF variation existed. 
The results together suggest that increased NAN is 
more lil¢ely to occur in subjects with asthma with 
higher serum ECP and BAL PGD 2 levels. 
So far, contradictory results have been re- 
ported on the recruitment of leukocytes to the 
airways at night in nocturnal asthma. Martin et 
al. 3 demonstrated significant increases in num- 
bers of eosinophils and lymphocytes in BAL fluid 
in association with increases in total white blood 
cell counts and neutrophil counts. In contrast, 
Jarjour et al. 4 did not find changes in BAL cell 
count in their subjects with nocturnal asthma, 
which corresponds with our findings. A compar- 
ison of patient characteristics of these two stud- 
ies and ours shows that the subjects with noctur- 
nal asthma in the study of Martin et al. generally 
had more severe asthma, with lower mean FEV 1 
values and higher circadian PEF variations at 
home. It is therefore possible that only in severe 
NAN an association can be found with pro- 
nounced infiltration of inflammatory cells into 
the airways, as recovered by BAL fluid. Further- 
more, in both of the other studies most of the 
subjects; used theophylline at the time of inves- 
tigation, whereas our subjects did not use theo- 
phylline, and maintenance therapy was withheld 
from 4 weeks before the start of the study. 
Although Martin et al. reported that the mean 
serum theophylline concentrations at 16:00 and 
04:00 hours did not differ, it is not clear whether 
individual differences in serum concentrations 
were observed. Changes in theophylline levels 
are known to modulate PB eosinophil num- 
bers, 25 and we do not exclude the possibility that this 
may have affected airway leukocyte traffic in their 
study as well. 
Contradictory results have also been reported 
on variations of PB eosinophil numbers and their 
activity between 04:00 and 16:00 hours in subjects 
with nocturnal asthma. Because the eosinophil 
shows a circadian chronobiologic rhythm with the 
highest value at night around 2:00 AM in normal 
subjects, 9 equal or increased numbers are likely to 
be found at night, depending on the time point of 
investigation. Eosinophil numbers in subjects with 
nocturnal asthma were reported to be either nor- 
maP and increased 5, 6 at 4:00 AM, or decreased. 7 In 
our study PB eosinophil numbers increased at 
night, without a difference between the three 
groups, whereas no variation in ECP levels be- 
tween 04:00 and 16:00 hours was found in the 
group with increased circadian PEF variation. Fitz- 
patrick et al. 7 reported decreased eosinophil 
counts, together with reduced serum ECP levels 
during the night and suggested these findings to be 
compatible with the involvement of a late asth- 
matic reaction in the pathogenesis of nocturnal 
asthma, although it cannot be excluded that the 
use of inhaled and oral corticosteroids in the latter 
study may have affected the results. 6 
Interestingly, subjects with asthma with in- 
creased circadian PEF variation could be distin- 
guished from subjects with asthma without in- 
creased circadian PEF variation by significantly 
higher levels of PGD 2 in BAL and ECP in serum at 
16:00 hours, suggesting that increased nocturnal 
airway obstruction in subjects with asthma occurs 
in those subjects with a preexisting more severe 
degree of inflammation. PGD2 is the major pros- 
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FIG. 3. Relationship between serum ECP levels at 16:00 
hours and circadian PEF variation in all subjects with 
asthma (r = 0.61, p = 0.01). 
tanoid release product of mast cells, although 
other cells in the airways such as alveolar macro- 
phages and eosinophils can synthesize PGD 2 as 
well. 26 Indirect evidence of a role for mast cell 
activation in nocturnal asthma has been suggested 
by findings that subjects with asthma with in- 
creased NAN showed a higher airway hyperre- 
sponsiveness to adenosine 5'-monophosphate, 1 
which exerts its airway constrictive ffect mainly by 
mast cell activation. On adenosine 5'-monophos- 
phate provocation, PGD 2 levels in the BAL fluid 
have been reported to be increased. 2vInhalation of 
a noncontractile dose of PGD 2 has been shown to 
potentiate airway hyperresponsiveness to metha- 
choline and histamine. 2s Therefore release of 
PGD 2 may play an important role in the increased 
airway hyperresponsiveness at night, underlying 
increased NAN in asthma. 
Increased serum ECP levels in subjects with 
asthma with increased NAN were not accompa- 
nied by increased eosinophil activation in BAL 
fluid in our study. It is possible that measurement 
of eosinophil activation parameters in BAL fluid 
does not fully reflect eosinophil activation in the 
airways or only at a more severe stage of airway 
inflammation. Studies on biopsy specimens ob- 
tained from the bronchial wall may reveal additional 
information about the involvement of eosinophil 
activation in increased NAN in asthma. 
In contrast o the observed circadian fluctua- 
tions in PB samples, we did not find evidence for 
circadian fluctuations in cell number and media- 
tors in the BAL fluid. In healthy subjects the 
various PB cell types show different circadian 
rhythms, resulting in higher numbers of circulating 
lymphocytes and eosinophils and lower numbers of 
neutrophils during the night. 9 These fluctuations 
were not found in the BAL cell numbers. BAL 
lymphocyte numbers did not change at night, 
whereas eosinophil numbers increased together 
with the neutrophil numbers in the control group 
and the asthma group without circadian PEF 
rhythm. However, we did not observe these 
changes in the asthma group with increased circa- 
dian PEF rhythm. Possibly these cells are en- 
trapped at night in increased numbers in the 
airway mucosa in subjects with asthma with in- 
creased NAN. This assumption eeds further in- 
vestigation. 
In conclusion, we found that increased NAN in 
subjects with asthma is on the whole not associated 
with a circadian fluctuation in cell number and 
inflammatory mediators in PB and BAL fluid. In 
general, higher numbers of eosinophils and levels 
of cell activation products are found in BAL fluid 
and PB from subjects with asthma as compared 
with control subjects. However, in subjects with 
asthma with increased nocturnal airways obstruc- 
tion most activation parameters did not differ- 
entiate them from subjects with asthma without 
nocturnal airways obstruction. Interestingly, signif- 
icantly higher levels of ECP in serum and PGD 2 in 
BAL fluid were present in subjects with asthma 
with increased nocturnal airways obstruction. 
These findings suggest that increased NAN occurs 
in subjects with asthma with ongoing increased 
nonspecific ellular activation during the day. 
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